TargetBeta
EGLN1
egl-9 family hypoxia inducible factor 1 · also SM-20, PHD2, ZMYND6, HIFPH2 · Zinc fingers MYND-type
4 programs in company-led studies act on EGLN1, from 4 companies: 2 in phase 3, 2 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| roxadustatrule | Astellas Pharma | phase 4 | 472 running | EGLN2, EGLN3, P4HTM | ChEMBL |
| enarodustatrule | Shionogi | phase 4 | 61 running | – | ChEMBL |
| daprodustatrule | GlaxoSmithKline | phase 3 | 331 running | EGLN2, EGLN3, P4HTM | ChEMBL |
| vadadustatrule | Akebia Therapeutics | phase 3 | 360 running | EGLN2, EGLN3 | ChEMBL |
Conditions their studies are in
- Anemia, 4 programs
- Kidney Failure, Chronic, 2 programs
- Renal Insufficiency, Chronic, 2 programs
- Diabetic Foot, 1 program
- Myelodysplastic Syndromes, 1 program
- Peripheral Vascular Diseases, 1 program
- Renal Insufficiency, 1 program
- Tendon Injuries, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- May 2027daprodustat · GlaxoSmithKline · phase 3 · NCT07300111
- Jun 2027enarodustat · Shionogi · phase 4 · NCT07079579
- Oct 30, 2027roxadustat · Astellas Pharma · phase 4 · NCT05970172
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.